GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (CHIX:PHARMa) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Pharming Group (CHIX:PHARMA) Future 3-5Y EPS without NRI Growth Rate : N/A (As of Jul. 23, 2025)


View and export this data going back to 2008. Start your Free Trial

What is Pharming Group Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Pharming Group's Future 3-5Y EPS without NRI Growth Rate is N/A.

Competitive Comparison of Pharming Group's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Pharming Group's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharming Group's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Pharming Group's Future 3-5Y EPS without NRI Growth Rate falls into.


;
;

Pharming Group  (CHIX:PHARMa) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Pharming Group Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Pharming Group's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharming Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (CHIX:PHARMa) » Definitions » Future 3-5Y EPS without NRI Growth Rate
Comparable Companies
XAMS:VVY XAMS:GLPG VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX INSM HKSE:01801 SMMT RPRX XKRX:196170 INCY HKSE:02269 OCSE:GMAB
Traded in Other Exchanges
PHAR:USA PHGUF:USA PHARM:Netherlands 0QCO:UK PHGN:Germany
Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Website
https://www.pharming.com
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Pharming Group Headlines

No Headlines